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Bovine colostrum is a health food supplement
which prevents NSAID induced gut damage
R J Playford, D N Floyd, C E Macdonald, D P Calnan, R O Adenekan, W Johnson,
R A Goodlad, T Marchbank
Abstract
Background—Non-steroidal anti-inflam-
matory drugs (NSAIDs) are eVective for
arthritis but cause gastrointestinal injury.
Bovine colostrum is a rich source of
growth factors and is marketed as a health
food supplement.
Aims—To examine whether spray dried,
defatted colostrum or milk preparations
could reduce gastrointestinal injury
caused by indomethacin.
Methods—EVects of test solutions, admin-
istered orally, were examined using an
indomethacin restraint rat model of gas-
tric damage and an indomethacin mouse
model of small intestinal injury. EVects on
migration of the human colonic carci-
noma cell line HT-29 and rat small intesti-
nal cell line RIE-1 were assessed using a
wounded monolayer assay system (used as
an in vitro model of wound repair) and
eVects on proliferation determined using
[3H]thymidine incorporation.
Results—Pretreatment with 0.5 or 1 ml
colostral preparation reduced gastric in-
jury by 30% and 60% respectively in rats.
A milk preparation was much less eYca-
cious. Recombinant transforming growth
factor â added at a dose similar to that
found in the colostrum preparation (12.5
ng/rat), reduced injury by about 60%.
Addition of colostrum to drinking water
(10% vol/vol) prevented villus shortening
in the mouse model of small intestinal
injury. Addition of milk preparation was
ineVective. Colostrum increased prolif-
eration and cell migration of RIE-1 and
HT-29 cells. These eVects were mainly due
to constituents of the colostrum with
molecular weights greater than 30 kDa.
Conclusions—Bovine colostrum could
provide a novel, inexpensive approach for
the prevention and treatment of the
injurious eVects of NSAIDs on the gut and
may also be of value for the treatment of
other ulcerative conditions of the bowel.
(Gut 1999;44:653–658)
Keywords: gastrointestinal tract; intestinal injury;
repair; nutrition
Non-steroidal anti-inflammatory drugs
(NSAIDs) are some of the most commonly
prescribed medicines used worldwide. Al-
though of undoubted eYcacy for the treatment
of musculoskeletal injury, it is well established
that chronic administration of NSAIDs causes
both gastric and intestinal damage. This
includes peptic ulceration and injury to the
small and large intestine causing increased per-
meability with protein and blood loss and
stricture formation.1–3
These pathologies often develop without
symptoms and are of particular significance in
the elderly where NSAIDs are often used for
several years. While acid suppressants and
prostaglandin analogues are of proven benefit
for the prophylaxis of NSAID induced peptic
ulceration, they are relatively ineVective in pre-
venting small and large intestinal injury.3 In
addition, use of prostaglandin analogues can be
complicated by diarrhoea and they are contra-
indicated in young women because of their
proabortive and teratogenic activity.4 Novel
therapeutic approaches are therefore required.
Colostrum is the milk produced for the first
few days after birth and is a rich natural source
of nutrients, antibodies, and growth factors for
the suckling neonate. Some studies suggest it
may be of value in eliminating infection and
stimulating growth of the neonatal gastro-
intestinal tract.5 6 Its value in the prevention
and treatment of adult gastrointestinal injury
is, however, largely unexplored. We therefore
examined the potential value of a defatted
bovine colostral preparation to prevent gastric
and small intestinal injury induced by the
NSAID indomethacin.
Methods
PREPARATION OF COLOSTRUM AND MILK
FRACTIONS
Colostrum and milk solutions for use in the
studies were prepared by Viable Bioproducts,
Turku, Finland. The initial colostrum and milk
whey solutions were passed through a microfil-
ter (0.2 µm pore). The final solutions were free
of fat and lactose and were reduced in most of
the major proteins including casein and lact-
albumin, with the remaining protein being
relatively rich in immunoglobulins and growth
factors. This form of colostrum is commer-
cially available as a health food supplement in
the USA, UK, and the rest of Europe, and is
marketed as a general “health promoting”
product, particularly suitable for athletes. The
total protein content of the colostrum and milk
preparations were 4.3 mg/ml. The concentra-
tions of the various growth factors present in
the colostrum preparation are incompletely
defined but include: insulin like growth factor I
Abbreviations used in this paper: BSA, bovine
serum albumin; EGF, epidermal growth factor; IGF,
insulin like growth factor; NSAID, non-steroidal
anti-inflammatory drug; TGF, transforming growth
factor.
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(IGF-I) and IGF-II, each at about 2 mg/l,
transforming growth factor â (TGFâ) at 25
µg/l, and epidermal growth factor (EGF) at 6
µg/l (data supplied by Scientific Hospital
Supplies, personal communication).
IN VIVO STUDIES
Rat gastric damaging model
The ability of colostrum and milk to prevent
gastric damage in rats stressed by indometha-
cin and restraint was assessed using our previ-
ously validated model.7 8 Rats were randomised
to receive 2 ml saline (containing bovine serum
albumin (BSA) 0.2 mg/ml), colostrum, or milk
at 25% and 50% vol/vol or 12.5 ng of
recombinant TGFâ1 made up in saline and
BSA. This dose of TGFâ1 was chosen as it is
similar to the total amount of TGFâ adminis-
tered to animals who received the colostrum at
25% vol/vol. All solutions also contained 2%
hydroxymethylpropylcellulose to reduce the
rate of gastric emptying. Thirty minutes after
gavage, all rats received indomethacin (20
mg/kg subcutaneously) and were placed in
Bollman type restraint cages. Animals were
killed three hours later and their stomachs
removed and inflated with 4 ml of 10% forma-
lin. The stomachs were randomly coded and
macroscopic and microscopic assessment of
injury were assessed in a blinded fashion. Mac-
roscopic injury was assessed using a dissecting
microscope (×10) with the aid of a reference
square grid and reported as the total area of
ulceration per stomach (mm2/stomach). The
stomachs were then embedded in wax and the
depth of damage assessed microscopically as
previously described.7 Briefly, microscopic in-
jury was graded with a score from 0 to 4 where:
0 = no damage, 1 = one small erosion (less than
0.5 mm), 2 = two small or one large erosion
(greater than 0.5 mm), 3 = two or more large
erosions, and 4 = any area of ulceration
extending to the muscularis mucosa.
Mouse small intestinal injury model
Protocol—Mice were randomised into groups of
20 and fed on a standard chow diet ad libitum.
The drinking water was supplemented with 5%
and 10% solution of colostrum or milk prepa-
rations for six days. Pilot studies showed that
the addition of these preparations did not affect
the total volume drunk (mean 5 ml/mouse/
day). Small intestinal injury was induced in half
of the animals of each group by administering
a single dose of indomethacin (85 mg/kg
subcutaneously) 24 hours before the end of the
study. Animals were killed 24 hours after
indomethacin as we have previously shown that
this is the time of maximal damage.9 In order to
assess changes in proliferation, each animal
also received vincristine (1 mg/kg intraperito-
neally), to induce metaphase arrest, two hours
prior to killing.
Assessment of damage and proliferation—The
wet weights of the various sections of the
gastrointestinal tract were recorded. Samples
of the small intestine and colon (defined by
their percentage length) were fixed in Carnoy’s
fluid and stored in 70% (vol/vol) ethanol.
Quantitation of intestinal proliferation and vil-
lus morphology (using microdissected villi)
were determined using previously published
methods.9
IN VITRO STUDIES
Cell proliferation
Rat intestinal epithelial (RIE-1) cells were a gift
from K Brown, Babraham Institute, Cam-
bridge, UK, and the human colonic carcinoma
cells (HT-29) were obtained from ECACC,
Porton Down, UK. RIE-1 and HT-29 cells
were grown in Dulbecco modified Eagle
medium (DMEM) containing glutamine and
10% foetal calf serum. EVects of colostrum,
milk, and EGF (positive control) were subse-
quently tested under serum starved conditions.
In addition, some wells also received TGFâ1 or
a panspecific anti-TGFâ polyclonal antibody
(R&D Systems, Minneapolis, USA). To assess
the rate of DNA synthesis, [3H]thymidine (2
µCi/well) was included 12 hours after the addi-
tion of the test factors and cells were left for a
further 12 hours. For each condition, the
stimulatory or inhibitory eVect of the solutions
was measured in quadruplicate in four separate
wells. Cell viability, determined by the ability to
exclude 0.2% trypan blue, was greater than
90% in both RIE-1 and HT-29 cell lines.
Cell migration as a model of wound repair
RIE and HT-29 cells were grown to confluence
in six well plates under the same conditions as
for the proliferation studies. The monolayers
were then wounded by scraping a disposable
pipette tip across the dishes, washed with fresh
serum free medium, and cultured in serum free
medium in the presence of various doses of
colostrum. The rate of movement of the
anterior edges of the wounded monolayers was
then determined by taking serial photomicro-
graphs at various times after wounding.8 An
inverted microscope (Nikon NK2) and a
NIKON H3 camera with 100-fold magnifica-
tion were used to obtain photomicrographs.
Identical regions were examined at each time
point by premarking the base of the plates to
facilitate alignment. Twenty measurements per
field were performed by placing a transparent
grid over the photograph and measuring the
distance moved from the original wound line.
All results are expressed as mean (SEM) of
four separate experiments.
STATISTICS
Studies were assessed using one way analysis of
variance (ANOVA) for rat gastric damaging
studies. Two way ANOVA was used for mouse
small intestinal studies (factors: diet and pres-
ence of indomethacin). One or two way
ANOVA were also used for the cell culture
studies as appropriate. Where a significant
eVect was seen (p<0.05), individual compari-
sons between groups were performed based on
the group means, residual, and degrees of free-
dom obtained from the ANOVA, a method
equivalent to repeated measures analysis.
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Results
IN VIVO STUDIES
Gastric injury model
Colostrum caused a dose dependent reduction
in the amount of gastric injury resulting from
indomethacin and restraint (fig 1A). Milk solu-
tion was much less eYcacious. Animals that
received 12.5 ng of recombinant TGFâ1
instead of the colostrum also had a reduction in
gastric injury of about 60% (macroscopic
injury score 17 (4) mm2/stomach versus 59
(10) mm2/stomach in control animals,
p<0.01). This dose of TGFâ1 was chosen as it
is similar to the total TGFâ content in 25%
vol/vol colostrum. Assessment using the micro-
scopic scoring system gave similar results
(fig 1B).
Small intestinal injury model
Morphometry—Compared with controls, sup-
plementation with colostrum or milk had no
eVect on villus height in animals who did not
receive indomethacin. At both the jejunal and
ileal sites, indomethacin caused a 25% reduc-
tion in the villus heights of control animals
(p<0.01; fig 2). Similar changes were seen in
animals which had received the 5% or 10%
milk or the 5% colostrum solution. Animals
receiving 10% colostrum, however, had only
about a 5% reduction in their villus height (NS;
fig 2).
Metaphases—The feeding of colostrum or
milk solution caused a small (10%), but
significant, reduction in the number of meta-
phases seen in the small intestine with a further
reduction (10%) seen when indomethacin was
coadministered (at 30% small intestinal site,
significance of the eVect of diet was p=0.001;
eVect of indomethacin, p=0.002; with no
interaction, p=0.72). This means that the pres-
ence of colostrum or milk did not influence the
amount of metaphase reduction induced by the
indomethacin in any of the groups.
In the colon, the addition of indomethacin
caused a 40% increase in the accumulation of
metaphases per crypt which was unaVected by
the presence of colostrum or milk supplemen-
tation (at the 25% colon site, significance of the
eVect of colostrum was p=0.611; eVect of
indomethacin, p<0.001; interaction, p=0.25).
IN VITRO STUDIES
Cell proliferation
HT-29 and RIE-1 cells showed a dose depend-
ent bell shaped increase in thymidine uptake in
response to colostrum, with the maximal effect
seen when added at 30% vol/vol, resulting in a
threefold increase in thymidine uptake. For the
dose response study utilising RIE-1 cells,
uptake increased from 19 900 (300) cpm
under basal circumstances to 59 200 (900)
cpm when incubated in the presence of colos-
trum at 30% vol/vol (p<0.01). In the subse-
quent series of experiments utilising size exclu-
sion separation, this eVect was found to be
mainly due to factor(s) with molecular weights
greater than 30 kDa with virtually all the pro-
stimulatory activity being found in this fraction
(fig 3). Addition of pure TGFâ1 to these cell
lines resulted in either no eVect on proliferation
or a small reduction in proliferation (data not
shown), showing that the proproliferative effect
of colostrum on these cell lines was not due to
its TGFâ content.
Figure 1 EVect of gavage with defatted colostrum and milk on the degree of gastric injury caused by indomethacin. The
degree of injury was assessed macroscopically (A), expressed as mm2/stomach and microscopically (B), where microscopic
injury was graded with a score from 0 to 4. Results expressed as mean (SEM) of six rats per group. **p<0.01 versus
amount of injury seen in animals receiving control solution.
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Cell migration as a model of wound repair
Addition of colostrum to HT-29 cells or RIE-1
cells resulted in a dose dependent increase in
cell migration. For the HT-29 cells, maximal
stimulation was seen at 30% vol/vol, resulting
in a fourfold increase in migration. Similar
results were seen with the RIE-1 cell line. Size
exclusion studies showed that predominant
promigratory activity was present in both the
10–30 kDa (accounting for about 40% of the
eVect of adding whole colostrum) and the >30
kDa fractions (accounting for about 60% of the
eVect of adding whole colostrum; fig 4). These
percentage activities were similar in both cell
lines.
Discussion
We have used several well validated in vivo and
in vitro models to investigate the potential
value of defatted milk and colostrum prepara-
tions in reducing NSAID induced gastro-
intestinal damage. Animal models showed that
gastric and small intestinal injury caused by
indomethacin could be reduced by colostrum
and that a similarly prepared milk solution was
far less eYcacious.
For the in vitro studies, rat small intestinal
(RIE-1) and human colonic (HT-29) cells were
used to show that these eVects were not species
specific and because administration of
NSAIDs causes damage throughout the entire
gastrointestinal tract. Studies examining the
potential beneficial eVect of colostrum on gas-
tric injury were performed using rats as we have
previously validated this model for other
growth factor studies (for example, Playford et
al8). Similarly, mice were used for studying the
eVect of colostrum on indomethacin induced
small intestinal injury as we have previous
experience of using this model to assess eVects
of other regulatory peptides.9 In addition, we
have found that mouse tissue is much easier to
process and microdissect than the equivalent
rat tissue (unpublished observation).
Colostrum is the milk produced by the
mother for the first few days after birth and is
much richer in growth factors and antibodies
than ordinary milk.5 6 10 Previous studies have
mainly examined the eVect of colostrum on
neonatal gut development; for example, por-
cine colostrum increases gut growth in suckling
pigs.11 There has been little research, however,
into the potential value of using milk or colos-
tral fractions for adult gastrointestinal condi-
tions. Bovine colostrum preparations are cur-
rently available in the USA, UK, and the rest of
Europe as “over the counter” health food sup-
plements. They do, however, contain large
amounts of potent growth factors which we
have shown are capable of influencing cell
growth and migration in vitro and reducing
indomethacin induced gut injury in vivo.
When an acute mucosal injury occurs, the
initial phase of the repair process is the rapid
migration of surviving cells over the denuded
area, to reestablish a continuous epithelial
layer. This begins within the first hour
following injury and is termed “restitution”. It
is followed by a much slower increase in cell
proliferation and remodelling.12 Our in vitro
studies showed that the colostrum preparation
studied was able to stimulate both migration
and proliferation. Size exclusion studies
showed that the majority of the biological
activity involved in stimulating cell migration
and proliferation in vitro could be found in the
>30 kDa fraction. Epidermal growth factor
and transforming growth factor á can both
mediate increases in proliferation and migra-
tion; however, both have a molecular weight of
about 6 kDa and are therefore too small to
account for our results. TGFâ is present in
colostrum in a high molecular weight form
(about 80 kDa) which is converted to a lower
molecular weight form (about 25 kDa) when it
comes into contact with an acidic environment
(pH<2), such as gastric juice.13 Although
TGFâ is known to stimulate restitution of
intestinal epithelial cells,14 it is unlikely to be
relevant to our finding of increased prolifera-
tion as the present studies have shown that
addition of recombinant TGFâ1 had either no
eVect or a slight inhibitory eVect on growth.
The identities of the large molecule(s) respon-
sible for the proproliferative eVects of bovine
colostrum are unclear but may include bovine-
colostrum derived growth factor. The structure
of this molecule is incompletely determined
but it is known to have a molecular weight of
about 30–35 kDa, and be structurally related to
platelet derived growth factor; it has been
shown to stimulate proliferation of mouse
fibroblast 3T3 cells.15 16 In contrast to the
results from the in vitro work, our in vivo stud-
ies suggested that members of the TGFâ
Figure 3 EVect of defatted colostrum on cell proliferation
in RIE-1 cells. Results expressed as mean (SEM).
*p<0.05, **p<0.01 versus cells grown without colostrum.
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family were key components of the colostrum
in its ability to prevent gastric injury in the rat
model. Administration of recombinant TGFâ1,
when given alone, reduced injury to a similar
extent to that which occurred after administer-
ing colostrum. Studies employing neutralising
antibodies could potentially shed light on
which are the major peptides involved in these
responses. There are, however, very limited
data about the cross reactivity of commercially
available antibodies (usually raised against
human or murine forms) against the bovine
homologues, seriously limiting the interpret-
ation of such experiments. In addition, it is
likely that more than one growth factor is
important in these responses.
Non-steroidal anti-inflammatory drugs are
of undoubted benefit for the treatment of
musculoskeletal injury and are widely used;
approximately 13 million patients in the USA
regularly take NSAIDs for arthritic
conditions17 and a prevalence study from Swe-
den found 8% of the total population were tak-
ing NSAIDs.18 However, 2–4% of patients who
take an NSAID for a year develop serious
gastrointestinal complications including peptic
ulceration and bleeding from the stomach and
small intestine.19–21 Many of these complica-
tions develop in patients who have no warning
symptoms and elderly patients taking NSAIDs
are at particular risk. Current therapeutic
options include coadministration of damage
limiting drugs, particularly acid suppressants
and prostaglandin analogues or using the rela-
tively selective (and expensive) COX-II inhibi-
tors. However, none of these options are
optimal; acid suppressants and prostaglandin
analogues are able to reduce gastric injury but
are relatively ineYcient in preventing small
intestinal damage, as shown by studies which
found that the major increase in small intestinal
permeability caused by indomethacin could
only be partially reduced by coadministration
of synthetic prostaglandins.3 In addition,
prostaglandin analogues induce diarrhoea in a
proportion of patients and are relatively
contraindicated in women of child bearing
potential because of their proabortive and tera-
togenic properties.4 The COX-II inhibitors
currently available are not completely selective
and are associated with gut injury,22 particu-
larly in patients requiring higher doses.23 All of
the present therapeutic options are therefore
suboptimal and new approaches are required.
Indomethacin causes damage to the gastro-
intestinal tract by several mechanisms includ-
ing reduction of mucosal prostaglandin levels,
reduction of mucosal blood flow, stimulating
neutrophil activation, and possibly also stimu-
lating apoptosis.24 It is likely that many of these
mechanisms will be influenced by the numer-
ous growth factors present in the colostrum
preparation. We have previously shown that
several of these peptides, for example, EGF
and TGF á, are susceptible to digestion from
luminal proteases when administered alone25
and that peptides involved in mucosal repair
can act in a synergistic fashion if
coadministered.26 There are therefore several
reasons why the use of this preparation, as
opposed to giving a single recombinant pep-
tide, might be particularly beneficial. It is also
important to note that our studies show that
the division between “food products” and
“drugs”, when considered in terms of biologi-
cal activity, is far from clear. The colostrum
preparation used for these studies is currently
considered to be a food product for licensing
purposes. Based on our results, we consider
that products such as this should be considered
as “nutriceuticals” as they contain potent
biologically active molecules.
In summary, we have shown that this colos-
trum preparation has major beneficial eVects in
preventing NSAID induced gut injury in a
variety of in vivo and in vitro models. Further
studies are underway to determine its value in
patients taking long term NSAIDs and in the
treatment of other ulcerative conditions of the
bowel, such as necrotising enterocolitis and
inflammatory bowel disease, where therapy is
suboptimal and novel approaches are required.
The authors acknowledge the Wellcome Trust, Medical
Research Council, and Scientific Hospital Supplies for funding.
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